Zinzino group revenue increased with a total of 24%, compared with the previous year.
The revenue in February for Zinzino's sales markets increased by 23 % and amounted to SEK 109.6 (89.0) million. Faun Pharma's external sales increased by 34 % and amounted to SEK 8.7 (6.5) million. Overall, the Group increased revenues by 24 % to SEK 118.3 (95.5) million compared with the previous year.
Accumulated revenue for January - February 2023 increased by 21% to SEK 247.7 (204.5) million.
Revenues were distributed as follows:
Regions,MSEK 23-Feb 22-Feb Change YTD 2023 YTD 2022 Change
The Nordics 23.2 21.5 8% 46.7 47.5 -2%
Central 26.9 18.5 45% 55.4 36.9 50%
Europe
East Europe 25.2 23.3 8% 58.0 52.0 12%
South & West 14.4 11.2 29% 30.3 23.3 30%
Europe
The Baltics 6.0 5.2 15% 13.4 11.6 16%
North 6.5 4.3 51% 12.8 8.7 47%
America
Asia-Pacific 6.4 4.6 39% 10.9 10.3 6%
Africa 1.0 0.4 150% 2.4 0.8 200%
Zinzino 109.6 89.0 23% 229.9 191.1 20%
Faun Pharma 8.7 6.5 34% 17.8 13.4 33%
Zinzino 118.3 95.5 24% 247.7 204.5 21%
Group
Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA
-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
-Africa: South Africa
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Pictures for publication free of charge:
marketing@zinzino.com
Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: certifiedadviser@penser.se